In defense of Heather Bresch: She did everything right as Mylan CEO, but still …; Pittsburgh Post-Gazette, 10/6/16

Chris Allison, Pittsburgh Post-Gazette; In defense of Heather Bresch: She did everything right as Mylan CEO, but still … :

"Were the actions of Ms. Bresch and her management team legal? Yes. Were they reasonable, given her mandate from Mylan’s board of directors and the company’s shareholders? Yes.

But, just because actions comply with the law and fall within the norms of sound business practices, that doesn’t mean a company should take them...

In my lectures on corporate ethics, I tell students that, when they face an ethical crossroads in business, they should ask themselves two questions. Would they feel proud to have their decision and its outcome featured on the front page of the newspapers? Would they be happy telling their children what they had done as they tucked them into bed at night?

Heather Bresch and other folks at Mylan didn’t do anything wrong. But they should have asked themselves those questions."

Members Of Congress Rip Into Mylan CEO; Huffington Post, 9/21/16

Lauren Weber, Huffington Post; Members Of Congress Rip Into Mylan CEO:

"“To have companies like yours take advantage of the situation, take advantage of these people who are really in need of this medication, I think it speaks to something that we are better than that,” Rep. Lacy Clay (D-Mo.) said. “How did we get to this point that we have a culture like this in corporate America that wants to stick it to consumers?”...

Cummings emphasized his disgust that pharmaceutical companies would continue to ratchet up drug prices for life-saving medication and said he hoped Bresch would apologize. She did not.

“After Mylan takes our punches, they’ll fly back to their mansions in their private jets and laugh all the way to the bank while our constituents suffer, file for bankruptcy, and watch their children get sicker and die,” Cummings said. “It’s time for Congress to act.”"

U.S. lawmakers demand investigation of $100 price hike of lifesaving EpiPens; Washington Post, 8/23/16

Ariana Eunjung Cha, Washington Post; U.S. lawmakers demand investigation of $100 price hike of lifesaving EpiPens:

"The medication itself isn’t expensive. Analysts calculate that the dosage contained in a single pen is worth about $1. It’s the company’s proprietary pen injector that makes up the bulk of the cost...

A profile in Fortune in 2015 described her rise in colorful terms:

Bresch, a 46-year-old who’s spent more than half her life at Mylan, has steered the company’s transformation from a quirky outfit run out of a West Virginia trailer to a global operator with 30,000 employees in 145 countries. Born into politics—her father, Joe Manchin, is a longtime West Virginia Democratic stalwart who’s now a U.S. senator—Bresch has mastered the regulatory world. Since becoming CEO in 2012, she’s overseen a major revenue increase; Mylan projects sales of up to $10.1 billion this year, up from $6.1 billion in 2011…

Under Bresch’s leadership, Mylan has also stumbled through a series of ethically messy mishaps and public relations gaffes. Mylan’s inversion took place just as uproar over the tactic reached a fever pitch on Capitol Hill. (Among the politicians who denounced the move was Bresch’s own father, though he later changed his mind.) Critics have called out the company for unusually high executive pay packages, questionable use of company jets, and murky relationships with board members. Then there’s “the Heather Bresch situation,” as she herself calls it, a scandal surrounding her executive MBA credentials—when you Google her name, the episode still ranks even higher than her official Mylan bio."